VEGFA and age-related macular degeneration: A study combining looking at at-risk AMD genotypes (SNPs in CFH, and ARMS2) with those SNPs identified in the angiogenesis pathway (SNPs in VEGFA, VEGF receptor KDR, LRP5 and FZD4) showed that patients with four high-risk alleles in CFH and ARMS2 were younger at age of onset of neovascular AMD and failed to show a visual improvement after ranibizumab treatment (S59).